UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000048787
Receipt number R000053918
Scientific Title Optimal dose of long-acting insulin analogue for withdrawal of artificial pancreas after hepatectomy -pilot study-
Date of disclosure of the study information 2022/08/30
Last modified on 2022/08/29 21:30:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Appropriate Dosage of Long-acting Insulin at the Time of Artificial Pancreas Withdrawal

Acronym

Appropriate Dosage of Long-acting Insulin at the Time of Artificial Pancreas Withdrawal

Scientific Title

Optimal dose of long-acting insulin analogue for withdrawal of artificial pancreas after hepatectomy -pilot study-

Scientific Title:Acronym

Optimal dose of long-acting insulin analogue for withdrawal of artificial pancreas after hepatectomy -pilot study-

Region

Japan


Condition

Condition

liver cancer, Diabetes

Classification by specialty

Endocrinology and Metabolism Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To find an appropriate formula to determine the amount of long-acting insulin at the time of artificial pancreas withdrawal.

Basic objectives2

Others

Basic objectives -Others

Appropriate long-acting insulin dose at the time of artificial pancreas withdrawal

Trial characteristics_1

Others

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Approximate formula for determining basal insulin dose at the time of artificial pancreas withdrawal

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

55 years-old <=

Age-upper limit

82 years-old >=

Gender

Male and Female

Key inclusion criteria

A case of partial/ lobectomy of the liver with bedside type artificial pancreas STG-55 (Nikkiso)

Key exclusion criteria

Cases of withdrawal from artificial pancreas

Target sample size

27


Research contact person

Name of lead principal investigator

1st name Atsuhito
Middle name
Last name Tone

Organization

Okayama Saiseikai General Hospital

Division name

Department of Internal Medicine, Diabetes Center

Zip code

700-8511

Address

2-25 Kokutai-cho, Kita-ku, Okayama City

TEL

086-252-2211

Email

aitone@ms1.megaegg.ne.jp


Public contact

Name of contact person

1st name Toshihisa
Middle name
Last name Tahara

Organization

Okayama Saiseikai General Hospital

Division name

Department of Internal Medicine, Diabetes Center

Zip code

700-8511

Address

2-25 Kokutai-cho, Kita-ku, Okayama City

TEL

086-252-2211

Homepage URL


Email

tt.toshihisa.tahara@gmail.com


Sponsor or person

Institute

Okayama Saiseikai General Hospital

Institute

Department

Personal name



Funding Source

Organization

Okayama Saiseikai General Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama Saiseikai General Hospital

Address

2-25 Kokutai-cho, Kita-ku, Okayama City

Tel

086-252-2211

Email

tt.toshihisa.tahara@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

27

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 05 Month 01 Day

Date of IRB

2021 Year 08 Month 10 Day

Anticipated trial start date

2021 Year 09 Month 01 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Patients who underwent partial/ lobectomy of the liver between October 1, 2019 and May 31, 2021.

measurement item
The 24-hour insulin amount calculated from the insulin infusion rate at the time of withdrawal from the artificial pancreas, and the 24-hour insulin amount calculated from the insulin amount used in the artificial pancreas from the operation to the next morning , preoperative basal insulin level, fasting CPR, HbA1c, body weight, and lactic acid level


Management information

Registered date

2022 Year 08 Month 29 Day

Last modified on

2022 Year 08 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000053918


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name